CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis

Neurology: Neuroimmunology and NeuroInflammation

Volumn 1, Issue 2, 2014, Pages

  Mir, Fozia ^a   Lee, Donald ^a   Ray, Hetal ^a   Sadiq, Saud A ^a  

^a Uro Center of New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ANTIOXIDANT; BIOLOGICAL MARKER; GLUTATHIONE DISULFIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ASSAY; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL ALLERGIC ENCEPHALITIS; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 84930831716     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000021     Document Type: Article

References (35)

1. Lassman H, Bruck W, Lucchinetti C. The immunopathol-ogy of multiple sclerosis: an overview. Brain Pathol 2007;17:210-218.
2. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247-269.
3. Lassman H, Horssen JV, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012;8:647-656.
4. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004;251:261-268.
5. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001;14:271-278.
6. Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chem Res Toxicol 2008;21:172-188.
7. Montine KS, Quinn JF, Zhang J, et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 2004;128:117-124.
8. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ II. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990;87:9383-9387.
9. Mir F, Sadiq S. Elevated cerebrospinal fluid levels of an isoprostane, an oxidative stress biomarker in MS patients. Mult Scler J 2011;17:S53-S276.
10. Fam SS, Morrow JD. The isoprostanes: unique products of arachidonic acid oxidation - a review. Curr Med Chem 2003;10:1723-1740.
11. Milne GL, Yin H, Brooks JD, Sanchez S, Roberts LJ II, Morrow JD. Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol 2007;433:113-126.
12. Milne GL, Sanchez SC, Musiek ES, Morrow JD. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc 2007;2:221-226.
13. Pratico D, Rokach J, Lawson J, Fitzgerald GA. F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids 2004;128:165-171.
14. Oliveira SR, Kallaur AP, Reiche EM. Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J Neurol Sci 2012;321:49-53.
15. Miller E, Mrowicka M, Saluk-Juszczak J, Ireneusz M. The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem Res 2011;36:1012-1016.
16. Teunissen CE, Sombekke M, Pratico D. Increased plasma 8,12-iso-iPF2alpha-VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. Mult Scler 2012;18:1092-1098.
17. Greco A, Minghetti L, Sette G, Fieschi C, Levi G. Cere-brospinal fluid isoprostanes show oxidative stress in patients with multiple sclerosis. Neurology 1999;53:1876-1879.
18. Mattsson N, Haghighi S, Andersen O, et al. Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neurosci Lett 2007;414:233-236.
19. Sbardella E, Greco A, Pozzilli C. Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course. Mult Scler 2013;19:411-417.
20. Greco A, Minghetti L, Puopolo M, et al. Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis. J Neurol Sci 2004;224:23-27.
21. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
22. Stromnes IM, Goverman JM. Active induction of experimental allergic encephalomyelitis. Nat Protoc 2006;1:1810-1819.
23. Harris VK, Yan QJ, Vyshkina T, et al. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci 2012;313:167-177.
24. Harris VK, Donelan N, Yan QJ, et al. Cerebrospinal fluid fetuin - A is a biomarker of active multiple sclerosis. Mult Scler 2013;19:1462-1472.
25. Sadiq SA. Multiple sclerosis. In: Roland LP, editor. Merritt's Neurology. 11th ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2005:941-963.
26. Gajofatto A, Calabrese M, Benedetti MD, Monaco S. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers 2013;35:687-699.
27. Harris VK, Sadiq SA. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther 2009;13:225-244.
28. di Penta A, Moreno B, Reix S, et al. Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. PLoS One 2013;8:e54722.
29. Preynat-Seauve O, Coudurier S, Favier A, Marche PN, Villiers C. Oxidative stress impairs intracellular events involved in antigen processing and presentation to T cells. Cell Stress Chaperones 2003;8:162-171.
30. Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A. Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int 1999;56:471-478.
31. Khasawneh FT, Huang JS, Mir F, Srinivasan S, Tiruppathi C, Le Breton GC. Characterization of isoprostane signaling: evidence for a unique coordination profile of 8-iso-PGF(2alpha) with the thromboxane A(2) receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets. Biochem Pharmacol 2008;75:2301-2315.
32. Wong-Ekkabut J, Xu Z, Triampo W, Tang IM, Tieleman DP, Monticelli L. Effect of lipid peroxidation on the properties of lipid bilayers: a molecular dynamics study. Biophys J 2007;93:4225-4236.
33. Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and disorders. Subcell Biochem 2008;49:241-268.
34. Palmeira CM, Santos MS, Carvalho AP, Oliveira CR. Membrane lipid peroxidation induces changes in gamma-[3H]aminobutyric acid transport and calcium uptake by synaptosomes. Brain Res 1993;609:117-123.
35. Limmroth V. Multiple sclerosis: oral BG12 for treatment of relapsing-remitting MS. Nat Rev Neurol 2013;9:8-10.